FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review

The FDA has published a Transparency Roadmap outlining its fiscal year 2026 milestones and fiscal year 2027 priorities across five areas of agency disclosure: complete response letters, investigational and marketing application lifecycle, new approach methodologies and novel biomarkers, patient-centered labeling, and compliance and inspectional records.¹

The post on FDA Voices, authored by Lowell M. Zeta, JD, acting chief of staff and deputy commissioner for strategic initiatives, frames transparency not only as a good-government value but as a mechanism for accelerating medical innovation.

"An agency that is open about its reasoning and processes is one that innovators can navigate with confidence, that investors can trust with capital, and that patients can rely on for honest answers," Zeta writes.

Complete response letters and application disclosures

The roadmap opens with complete response letters (CRLs), where the FDA describes disclosure as a pivotal mechanism for transparency. The agency cites a 2015 internal analysis finding that 85% of its safety and efficacy concerns were not mentioned by sponsors when publicly announcing non-approvals. The CRL disclosure initiative launched in 2025 with the release of more than 200 letters covering applications from 2020 to 2024 is described as a watershed moment, with disclosure now positioned as a standing practice.

The roadmap also details a Memorandum of Understanding (MOU) signed in August 2026 between the FDA and the US Securities and Exchange Commission (SEC), establishing a formal framework for sharing nonpublic information between the two agencies. Under the agreement, the FDA may share information related to FDA-regulated products, activities, and the firms involved, which the SEC can use in reviews of public company filings, enforcement investigations, and civil actions.

Beyond CRLs, the agency is encouraging sponsors to publicly disclose the existence of an Investigational New Drug Application (IND) upon filing, noting that approximately 96% of novel drug or biologic filings are already disclosed by companies or third parties. The FDA also intends to pursue expanded post-approval scientific data disclosures, including publication of Clinical Study Reports (CSRs) for approved applications and piloting expanded clinical dataset transparency.

New approach methodologies and real-world evidence

On emerging evidence tools, the FDA launched a publicly accessible new approach methodologies (NAMs) Database of Use Case Examples in September 2026, featuring 25 examples drawn from existing public review materials illustrating how NAMs have been incorporated into approved drug applications. A September 2026 direct final rule also updated regulatory terminology to explicitly recognize NAMs as valid nonclinical testing methods.

The agency is also aiming to provide greater visibility into the use of real-world evidence (RWE) in submissions and of decentralized trials generating evidence through digital health technologies, consistent with its PDUFA VII commitments.

Labeling, inspections, and the broader picture

On labeling, the FDA intends to issue a final rule requiring a new one-page patient medication information (PMI) document for prescription drug products used on an outpatient basis, with standardized format and content designed to be accessible to patients with low health literacy.

On inspections, the agency plans to proactively publish redacted Form 483s and establishment inspection reports where appropriate, extending transparency into its compliance and bioresearch monitoring activities.

Industry navigating an evolving FDA

The roadmap lands at a moment when sponsors are still recalibrating to a period of significant agency change. Earlier this year, Applied Clinical Trials spoke with Charlie Paterson, partner at PA Consulting, about how reduced FDA capacity and staff turnover in 2025 reshaped regulatory engagement and planning across the development lifecycle.²

Paterson described uncertainty as cutting across multiple stages, from initial applications through late-stage approval.

"Organizations are seeing uncertainty during initial applications and feedback, leading to more conservative holds before studies even begin," he said. "Further downstream, during tech transfer and the period between last patient last visit and approval, timelines are also elongating because capacity can't meet volume. That's driving concern and pushing activity outside the US."

His assessment of where things stood earlier in the year gives the Transparency Roadmap additional context: sponsors have been compensating for unpredictability by benchmarking against other regulatory jurisdictions and front-loading preparation.

A more open, predictable FDA—which the roadmap explicitly aims to support—is precisely what Paterson described the industry as needing.

References

1. Transparency Makes Modern Regulatory Science Stronger — FDA’s Transparency Roadmap. FDA Voices. October 2, 2026. https://www.fda.gov/news-events/fda-voices/transparency-makes-modern-regulatory-science-stronger-fdas-transparency-roadmap
2. Regulatory Uncertainty Emerges Across the Drug Development Lifecycle. Applied Clinical Trials. February 3, 2026. https://www.appliedclinicaltrialsonline.com/view/regulatory-uncertainty-emerges-drug-development-lifecycle